Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. reports news on its precision oncology business, including commercialization of KOMZIFTI™ (ziftomenib), an FDA-approved once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. Company updates also cover small-molecule drug candidates designed to target cancer signaling pathways across hematologic malignancies and solid tumors.
Recurring KURA developments include financial results, corporate updates, clinical data presentations, collaboration-related milestones, healthcare conference participation and Nasdaq inducement grants. News on darlifarnib (KO-2806) follows the company’s farnesyl transferase inhibitor program, including studies in combination with cabozantinib for clear cell renal cell carcinoma.
Kura Oncology (Nasdaq: KURA) announced that on August 3, 2026, its Board Compensation Committee granted inducement awards of nonstatutory stock options to purchase 104,500 shares of common stock to six new employees under the 2023 Inducement Option Plan, as amended.
The options have an exercise price of $9.19 per share, equal to the August 3, 2026 closing price, and vest over four years: 25% after one year and the remaining shares monthly over the following 36 months, subject to continued service. The awards were approved as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Kura Oncology (Nasdaq: KURA) will report its second quarter 2026 financial results after the close of U.S. financial markets on Wednesday, August 12, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and provide a corporate update.
The live webcast and archived replay will be available on Kura’s website under the Investors > Events and Presentations section. Kura is a biopharmaceutical company focused on precision medicines for cancer, including KOMZIFTI (ziftomenib), an FDA-approved, once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia.
Kura Oncology (Nasdaq: KURA) reported updated Phase 1a data from the FIT-001 trial of darlifarnib plus cabozantinib in cabozantinib-naïve, pretreated patients with locally advanced or metastatic clear cell renal cell carcinoma (ccRCC). Among 34 evaluable patients, objective response rates ranged from 33% to 50% across darlifarnib dose levels, with a median progression-free survival of 13 months across pooled doses and median duration of response not yet estimable at most levels due to ongoing responses.
The combination showed durable clinical benefit, with more than half of patients on treatment at data cutoff, and a manageable safety profile in 72 RCC patients, generally consistent with the individual drugs. According to Kura Oncology, these results support further development of darlifarnib plus cabozantinib, and a global, randomized Phase 1b portion comparing the combination versus cabozantinib alone is underway to define a recommended Phase 3 dose ahead of a planned registrational study in 2028.
Kura Oncology (Nasdaq: KURA) will present updated long-term follow-up data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced clear cell renal cell carcinoma at the 2026 Kidney Cancer Research Summit in Boston on July 24, 2026.
The company is also enrolling a global randomized Phase 1b trial comparing the combination versus cabozantinib alone to inform a planned registrational Phase 3 study in 2028 and will host a virtual investor call on July 27, 2026.
Kura Oncology (Nasdaq: KURA) reported inducement equity grants under Nasdaq Listing Rule 5635(c)(4) to five new employees. On July 1, 2026, the compensation committee granted nonstatutory stock options for 68,750 shares at a per-share exercise price of $10.78, vesting over four years.
Kura Oncology (Nasdaq: KURA) and Kyowa Kirin reported long-term Phase 1/2 KOMET-007 data for ziftomenib + 7+3 in newly diagnosed NPM1-m and KMT2A-r AML.
12‑month OS was 94% for NPM1-m and 71% for KMT2A-r; CRc reached 96% and 90%, with high MRD negativity and a generally manageable safety profile supporting the ongoing Phase 3 KOMET-017 program.
Kura Oncology (Nasdaq: KURA) granted inducement stock options on June 1, 2026 to four new employees under its 2023 Inducement Option Plan. The awards cover 53,000 shares at an exercise price of $9.04 per share, vesting over four years under Nasdaq Listing Rule 5635(c)(4).
Kura Oncology (Nasdaq: KURA) reported preliminary Phase 1a data for darlifarnib + adagrasib, showing confirmed objective response rates of 67% in KRAS G12C pancreatic cancer, 50% in lung cancer and 29% in KRAS inhibitor-naïve colorectal cancer.
The company plans a new darlifarnib combination platform study, starting with darlifarnib + daraxonrasib in 2L+ KRAS-mutant pancreatic cancer, expected to enter Phase 1a in early 2027, and will host a virtual investor event on June 3, 2026.
Kura Oncology (Nasdaq: KURA) and Kyowa Kirin reported updated Phase 1a/b KOMET-007 data in relapsed/refractory NPM1-mutated AML using ziftomenib + venetoclax/azacitidine.
At 600 mg, venetoclax-naïve patients showed 87% ORR, 70% CRc and median OS not reached; venetoclax-experienced patients had 48% ORR, 24% CRc. The triplet showed a generally manageable safety profile with low differentiation syndrome and limited QTc events.
Kura Oncology (Nasdaq: KURA) reported Phase 1a data from the FIT-001 trial of darlifarnib + adagrasib in KRAS G12C-mutated advanced solid tumors.
- Tumor shrinkage in 77% (20/26) of response-evaluable patients; 94% (15/16) in KRASi-naïve patients
- ORR: 67% in PDAC, 50% in NSCLC, 29% in KRASi-naïve CRC
- Clinical activity seen across dose levels and tumor types, including heavily pretreated and KRASi-experienced patients
- 37% of patients remained on treatment at March 25, 2026 cutoff
- Combination described as well tolerated with a manageable safety profile; darlifarnib 8 mg will not be advanced further
- ASCO 2026 presentation on May 30, and a virtual investor event on June 3, 2026